CovidV2, Main, Exploration, bibRecord, 000F57

Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis

Identifieur interne : 000F57 ( Main/Exploration ); précédent : 000F56; suivant : 000F58

Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis

Auteurs : Masaji Okada ; Yoko Kita ; Satomi Hashimoto ; Hitoshi Nakatani ; Shiho Nishimastu ; Yumiko Kioka ; Yasuko Takami

Source :

Human Vaccines & Immunotherapeutics [ 2164-5515 ] ; 2016.

RBID : PMC:5328238

Abstract

ABSTRACT

[Purpose] Multi-drug resistant (MDR), Mycobacterium tuberculosis (TB) is a big problem in the world. We have developed novel TB therapeutic vaccine (HVJ-E/HSP65 DNA +IL-12 DNA).

[Methods and Results] DNA vaccine expressing TB heat shock protein 65 and IL-12 was delivered by the hemagglutinating virus of Japan (HVJ)-envelope. This vaccine provided remarkable protective efficacy and strong therapeutic efficacy against MDR-TB and XDR-TB in murine models. Furthermore, this vaccine provided therapeutic efficacy of prolongation of survival time of TB infected monkeys and augmented the immune responses.

Therefore, the preclinical tests were studied for clinical trial. The injection of 100 μg of the vaccine /mouse i.m. three times in two weeks induced significantly strong production of IFN-γ and IL-2. 100 μg and 200 μg DNA vaccine/mouse i.m. augmented the production of these cytokines compared with 25 μg DNA vaccine/mouse i.m.. The ratio of 100 μg pDNA to 1AU HVJ-E enhanced the production of IFN-γ and IL-2. The decrease in the number of M. tuberculosis in liver of mice was observed by the vaccination of 100μg pDNA. By using these conditions, safety pharmacology study and toxicology test is being studied in monkeys administered by GMP level DNA vaccines. By the toxicology test using monkeys, high dose GMP level vaccine/ monkey is administrated. Safety pharmacological study of repeated administration is also being investigated in GLP level.

Furthermore, we have planned to do clinical phase I trial. Targets are human patients with MDR-TB. The safety and tolerability of the vaccine will be evaluated.

[Conclusion and recommendations] These data indicate that our novel vaccine might be useful against tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical applications.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328238

DOI: 10.1080/21645515.2017.1264781
PubMed: 27960629
PubMed Central: 5328238

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis</title>
<author><name sortKey="Okada, Masaji" sort="Okada, Masaji" uniqKey="Okada M" first="Masaji" last="Okada">Masaji Okada</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kita, Yoko" sort="Kita, Yoko" uniqKey="Kita Y" first="Yoko" last="Kita">Yoko Kita</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hashimoto, Satomi" sort="Hashimoto, Satomi" uniqKey="Hashimoto S" first="Satomi" last="Hashimoto">Satomi Hashimoto</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nakatani, Hitoshi" sort="Nakatani, Hitoshi" uniqKey="Nakatani H" first="Hitoshi" last="Nakatani">Hitoshi Nakatani</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nishimastu, Shiho" sort="Nishimastu, Shiho" uniqKey="Nishimastu S" first="Shiho" last="Nishimastu">Shiho Nishimastu</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kioka, Yumiko" sort="Kioka, Yumiko" uniqKey="Kioka Y" first="Yumiko" last="Kioka">Yumiko Kioka</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Takami, Yasuko" sort="Takami, Yasuko" uniqKey="Takami Y" first="Yasuko" last="Takami">Yasuko Takami</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27960629</idno>
<idno type="pmc">5328238</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328238</idno>
<idno type="RBID">PMC:5328238</idno>
<idno type="doi">10.1080/21645515.2017.1264781</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000692</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000692</idno>
<idno type="wicri:Area/Pmc/Curation">000692</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000692</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000456</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000456</idno>
<idno type="wicri:Area/Ncbi/Merge">000664</idno>
<idno type="wicri:Area/Ncbi/Curation">000664</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000664</idno>
<idno type="wicri:doubleKey">2164-5515:2016:Okada M:preclinical:study:and</idno>
<idno type="wicri:Area/Main/Merge">000F59</idno>
<idno type="wicri:Area/Main/Curation">000F57</idno>
<idno type="wicri:Area/Main/Exploration">000F57</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis</title>
<author><name sortKey="Okada, Masaji" sort="Okada, Masaji" uniqKey="Okada M" first="Masaji" last="Okada">Masaji Okada</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kita, Yoko" sort="Kita, Yoko" uniqKey="Kita Y" first="Yoko" last="Kita">Yoko Kita</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hashimoto, Satomi" sort="Hashimoto, Satomi" uniqKey="Hashimoto S" first="Satomi" last="Hashimoto">Satomi Hashimoto</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nakatani, Hitoshi" sort="Nakatani, Hitoshi" uniqKey="Nakatani H" first="Hitoshi" last="Nakatani">Hitoshi Nakatani</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nishimastu, Shiho" sort="Nishimastu, Shiho" uniqKey="Nishimastu S" first="Shiho" last="Nishimastu">Shiho Nishimastu</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kioka, Yumiko" sort="Kioka, Yumiko" uniqKey="Kioka Y" first="Yumiko" last="Kioka">Yumiko Kioka</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Takami, Yasuko" sort="Takami, Yasuko" uniqKey="Takami Y" first="Yasuko" last="Takami">Yasuko Takami</name>
<affiliation><nlm:aff id="af0001"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Human Vaccines & Immunotherapeutics</title>
<idno type="ISSN">2164-5515</idno>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>ABSTRACT</title>
<p><bold>[Purpose]</bold>
 Multi-drug resistant (MDR), <italic>Mycobacterium tuberculosis</italic>
 (TB) is a big problem in the world. We have developed novel TB therapeutic vaccine (HVJ-E/HSP65 DNA +IL-12 DNA).</p>
<p><bold>[Methods and Results]</bold>
 DNA vaccine expressing TB heat shock protein 65 and IL-12 was delivered by the hemagglutinating virus of Japan (HVJ)-envelope. This vaccine provided remarkable protective efficacy and strong therapeutic efficacy against MDR-TB and XDR-TB in murine models. Furthermore, this vaccine provided therapeutic efficacy of prolongation of survival time of TB infected monkeys and augmented the immune responses.</p>
<p>Therefore, the preclinical tests were studied for clinical trial. The injection of 100 μg of the vaccine /mouse i.m. three times in two weeks induced significantly strong production of IFN-γ and IL-2. 100 μg and 200 μg DNA vaccine/mouse i.m. augmented the production of these cytokines compared with 25 μg DNA vaccine/mouse i.m.. The ratio of 100 μg pDNA to 1AU HVJ-E enhanced the production of IFN-γ and IL-2. The decrease in the number of M. tuberculosis in liver of mice was observed by the vaccination of 100μg pDNA. By using these conditions, safety pharmacology study and toxicology test is being studied in monkeys administered by GMP level DNA vaccines. By the toxicology test using monkeys, high dose GMP level vaccine/ monkey is administrated. Safety pharmacological study of repeated administration is also being investigated in GLP level.</p>
<p>Furthermore, we have planned to do clinical phase I trial. Targets are human patients with MDR-TB. The safety and tolerability of the vaccine will be evaluated.</p>
<p><bold>[Conclusion and recommendations]</bold>
 These data indicate that our novel vaccine might be useful against tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical applications.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Hashimoto, Satomi" sort="Hashimoto, Satomi" uniqKey="Hashimoto S" first="Satomi" last="Hashimoto">Satomi Hashimoto</name>
<name sortKey="Kioka, Yumiko" sort="Kioka, Yumiko" uniqKey="Kioka Y" first="Yumiko" last="Kioka">Yumiko Kioka</name>
<name sortKey="Kita, Yoko" sort="Kita, Yoko" uniqKey="Kita Y" first="Yoko" last="Kita">Yoko Kita</name>
<name sortKey="Nakatani, Hitoshi" sort="Nakatani, Hitoshi" uniqKey="Nakatani H" first="Hitoshi" last="Nakatani">Hitoshi Nakatani</name>
<name sortKey="Nishimastu, Shiho" sort="Nishimastu, Shiho" uniqKey="Nishimastu S" first="Shiho" last="Nishimastu">Shiho Nishimastu</name>
<name sortKey="Okada, Masaji" sort="Okada, Masaji" uniqKey="Okada M" first="Masaji" last="Okada">Masaji Okada</name>
<name sortKey="Takami, Yasuko" sort="Takami, Yasuko" uniqKey="Takami Y" first="Yasuko" last="Takami">Yasuko Takami</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F57 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F57 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:5328238
   |texte=   Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27960629" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidV2

This area was generated with Dilib version V0.6.33.
Data generation: Sat Mar 28 17:51:24 2020. Site generation: Sun Jan 31 15:35:48 2021

Serveur d'exploration Covid (26 mars)

Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis

Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Covid (26 mars)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.